Related references
Note: Only part of the references are listed.Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Alan K. Burnett et al.
LANCET ONCOLOGY (2015)
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
Harry J. Iland et al.
LANCET HAEMATOLOGY (2015)
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis
Naval Daver et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
Miguel A. Sanz et al.
BLOOD (2014)
A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
M. D. Seftel et al.
CURRENT ONCOLOGY (2014)
Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide
Gail J. Roboz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial
A. K. Burnett et al.
LEUKEMIA (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia
Karen A. Breen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
James Scott McClellan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia
Sai-Juan Chen et al.
BLOOD (2011)
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
Jae H. Park et al.
BLOOD (2011)
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
Giuseppe Avvisati et al.
BLOOD (2011)
Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
Ardeshir Ghavamzadeh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Modern Approaches to Treating Acute Promyelocytic Leukemia
Miguel A. Sanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry
S. Lehmann et al.
LEUKEMIA (2011)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Miguel A. Sanz et al.
BLOOD (2010)
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
Milena Sant et al.
BLOOD (2010)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
Francesco Lo-Coco et al.
BLOOD (2010)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Bayard L. Powell et al.
BLOOD (2010)
Rapid and Reliable Confirmation of Acute Promyelocytic Leukemia by Immunofluorescence Staining With an Antipromyelocytic Leukemia Antibody The M. D. Anderson Cancer Center Experience of 349 Patients
Nikolay D. Dimov et al.
CANCER (2010)
Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA
G. Avvisati et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy
Pau Montesinos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
Vikram Mathews et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
Hugues de The et al.
NATURE REVIEWS CANCER (2010)
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
Pau Montesinos et al.
BLOOD (2009)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2009)
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Pau Montesinos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
Syed Khizer Hasan et al.
BLOOD (2008)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy:: The Japan Adult Leukemia Study Group (JALSG) APL97 study
Norio Asou et al.
BLOOD (2007)
Is cytarabine useful in the treatment of acute promyelocytic leukemia?: Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
Lionel AdeS et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
E Estey et al.
BLOOD (2006)
DNA topoisomerase II in therapy-related acute promyelocytic leukemia
AR Mistry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
All-trans retinoic acid/AS2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
ZX Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Expression of cell-surface antigens in acute promyelocytic leukaemia
E Paietta
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2003)
The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease
AR Mistry et al.
BLOOD REVIEWS (2003)
All-trans retinoic acid in acute promyelocytic leukemia:: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
MS Tallman et al.
BLOOD (2002)
Share Paper
